News & Publications

Tuesday, December 2, 2025

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow^® Nebulizer System

News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow^® Nebulizer System.

^{*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.}
 

Read more

Customization is key

Read an interview with Lyn Baranowski, CEO of Avalyn Pharma in Drug Discovery News about the development of inhaled drug formulations for patients with pulmonary fibrosis and what made them decide to go with a customized eFlow^® Technology nebulizer.
 

Read more

Wednesday, March 26, 2025

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow^® Technology nebulizer.
 

^{*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.}            

Read more

Thursday, January 30, 2025

Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

News published by Savara Inc. concerning Molgramostim Nebulizer Solution, a novel investigational inhaled biologic, administered via an investigational eFlow^® Technology nebulizer.

Read more

Wednesday, December 18, 2024

Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

News published by Savara Inc. concerning MOLBREEVI for the potential treatment of aPAP, administered via an investigational eFlow^® Technology nebulizer.

*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
 

Read more

Wednesday, June 26, 2024

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

News published by Savara Inc. concerning Molgramostim Nebulizer Solution, a novel investigational inhaled biologic, administered via an investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, April 30, 2024

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

News published by Renovion Inc. concerning ARINA-1, a nebulized therapy administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, September 5, 2023 

Insmed Announces Positive Topline Results From Phase 3 ARISE Study of ARIKAYCE^® (amikacin liposome inhalation suspension) in Patients with NTM Lung Disease Caused by MAC

News published by Insmed presenting data from ARIKAYCE^® (amikacin liposome inhalation suspension), administered via the optimized eFlow^® Technology nebulizer Lamira^®.
 

Read more

Tuesday, June 27, 2023

Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Tuesday, May 2, 2023 

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, April 18, 2023 

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Thursday, March 30, 2023

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

News published by Avalyn Pharma concerning AP02 (inhaled nintedanib), administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Thursday, March 30, 2023

Renovion Receives FDA Fast Track Designation for ARINA-1 for the Prevention of BOS Progression in Lung Transplant Patients

News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Thursday, March 23, 2023 

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

News published by Avalyn Pharma concerning AP01 (inhaled pirfenidone), administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Wednesday, March 15, 2023

ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

News published by Recode Therapeutics concerning RCT1100, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Monday, January 09, 2023 

Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound

News published by Spexis concerning murepavadin, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Wednesday, November 02, 2022

First Patient Enrolled in Phase 2 Clinical Study Evaluating ARINA-1 for the Treatment of NCFBE

News published by Renovion Inc. concerning ARINA-1, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Thursday, August 25, 2022

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Wednesday, August 03, 2022 

Renovion Receives Notice of Study May Proceed Status for Lung Transplant Program

News published by Renovion Inc. concerning ARINA-1, a nebulized therapy in patients with a lung transplant, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Friday, June 17, 2022 

Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic

News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Thursday, December 30, 2021 

Polyphor closes merger with EnBiotix and is renamed Spexis

News published by Spexis concerning the closing of the merger of PARI’s partners Polyphor AG and EnBiotix Inc. and the change of name of the combined company to Spexis AG.
 

Read more

Tuesday, July 13, 2021 

Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

News published by Savara Inc. concerning molgramostim (inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)), administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Friday, June 25, 2021 

Dr. Stefan Seemann is appointed President of PARI Pharma GmbH

Dr. Stefan Seemann will replace Dr. Martin Knoch as President of PARI Pharma GmbH on July 1, 2021.
 

Read more

Tuesday, May 25, 2021 

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial​

News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Thursday, May 20, 2021 

Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference​​​​

News published by Insmed presenting data from, among others, ARIKAYCE^® (amikacin liposome inhalation suspension), administered via an optimized eFlow^® Technology nebulizer.​
 

Read more

Thursday, April 29, 2021 

Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021

News published by Zambon, whose liposomal cyclosporine A for inhalation (L CsA i), which is in clinical development for the potential treatment of BOS, is administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, March 23, 2021 

LAMIRA^®, an eFlow^® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE^® (amikacin liposome inhalation suspension)

PARI Pharma GmbH announces the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE^®
(amikacin liposome inhalation suspension) in Japan.
 

Read more

Monday, March 1, 2021 

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

News published by Santhera Pharmaceuticals concerning Lonodelestat in cystic fibrosis, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Thursday, January 7, 2021 

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE^® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

News published by Insmed Incorporated concerning ARIKAYCE, administered using Lamira^®, an optimized eFlow^® Technology nebulizer.
 

Read more

Tuesday, December 22, 2020 

Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin

News published by Polyphor concerning inhaled murepavadin, administered via an eFlow^® Technology nebulizer.
 

Read more

Tuesday, November 24, 2020 

Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin

News published by Polyphor concerning the development of inhaled murepavadin, administered via an eFlow^® Technology nebulizer.
 

Read more

Thursday, October 29, 2020

LAMIRA^®, an eFlow^® Technology nebulizer, is the only device to deliver Insmed’s ARIKAYCE^® Liposomal 590 mg Nebuliser Dispersion in the European Union

PARI Pharma GmbH announces the issue of the CE declaration of conformity for its optimized eFlow Technology LAMIRA Nebuliser System.

Read more

Thursday, October 22, 2020

PARI's optimized Investigational eFlow^® Technology nebulizer delivering well tolerated aerosols of AR-501 in Aridis´ Phase 1/2a clinical trial

PARI Pharma’s proprietary aerosol delivery platform, eFlow Technology, continues its long track record of success with Aridis Pharmaceuticals.
 

Read more

Friday, October 16, 2020 

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial

News published by Avalyn Pharma concerning AP01 (a formulation of pirfenidone optimized for delivery via inhalation), administered via an optimized eFlow^® Technology nebulizer.

Tuesday, October 13, 2020 

Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis

News published by Ionis Pharmaceuticals concerning IONIS-ENAC-2.5 Rx, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Friday, July 24, 2020 

Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options

News published by Insmed Incorporated concerning ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, administered with Lamira^®, an optimized eFlow^® Technology nebulizer.
 

Read more

Tuesday, July 7, 2020 

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE^® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease

News published by Insmed Incorporated concerning ARIKAYCE^® (amikacin liposome inhalation suspension), administered with Lamira^®, an optimized eFlow^® Technology nebulizer.
 

Read more

Thursday, June 18, 2020 

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

News published by Renovion, Inc. concerning their lead therapeutic candidate ARINA-1, administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Monday, June 1, 2020

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

News published by Biomarck Pharmaceuticals concerning its novel anti-MARCKS peptide BIO-11006 in non-small cell lung cancer (NSCLC), administered via an optimized eFlow^® Technology nebulizer.
 

Read more

Tuesday, April 28, 2020 

A new FDA Fast Track designation for Zambon

The designation is for L CsA i for the treatment of bronchiolitis obliterans syndrome, developed by Breath Therapeutics, a Zambon company

News published by Zambon concerning L-CsA-i, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Thursday, February 20, 2020 

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

News published by Breath Therapeutics concerning L-CsA-i, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Monday, December 16, 2019 

Kamada Announces Enrollment of First Patient into its Pivotal Phase 3 InnovAATe Clinical Trial of Inhaled AAT for the Treatment of Alpha-1 Antitrypsin Deficiency

News published by Kamada Ltd. concerning inhaled AAT, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, September 10, 2019 

Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis

News published by Santhera Pharmaceuticals concerning POL6014 in cystic fibrosis, administered with an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Thursday, July 25, 2019 

PARI Pharma spin-out Breath Therapeutics acquired by Zambon Pharma

News published by Zambon Pharma concerning the acquisition of biopharmaceutical company Breath Therapeutics

Read more

News published by Gimv concerning the sale of biopharmaceutical company Breath Therapeutics
 

News published by Sofinnova Partners concerning the sale of biopharmaceutical company Breath Therapeutics

Read more

Monday, May 20, 2019 

New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE^® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease

News published by Insmed Incorporated concerning ARIKAYCE^® (amikacin liposome inhalation suspension), administered with Lamira^®, an optimized eFlow^® Technology nebulizer.
 

Read more

Wednesday, May 1, 2019 

Sunovion to Present Data on LONHALA^® MAGNAIR^® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019

News published by Sunovion Pharmaceuticals Inc. presenting data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019.
 

Read more

Tuesday, March 26, 2019 

Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome.

News published by Breath Therapeutics concerning L-CsA-I, administered via an optimized investigational eFlow^® Technology nebulizer.
 

Read more

Tuesday, October 2, 2018 

PARI Pharma’s eFlow^® Technology device, LAMIRA^™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE^® (amikacin liposome inhalation suspension).

ARIKAYCE^® is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options
 

Read more

Thursday, December 7, 2017 

Magnair^TM an eFlow^® Closed System Nebulizer together with Sunovion’s Lonhala^TM is the first eFlow Technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD)

LONHALA MAGNAIR Inhalation Solution is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S.
 

Read more

The Importance of Mesh Nebulizer Configuration in mRNA-LNP Delivery Performance

Beike, H., Heine, B. (2025).

ONdrugDelivery, Issue 181 (December 2025), pp 24–27.

To Publication 

Effect of Nebulizer Breath-Guiding on Breathing Patterns

Heine, B. et al. (2025).

Drug Delivery to the Lungs conference proceedings, Volume 36, 2025
 

To Publication

Analysis of mRNA Delivery Performance via Vibrating Mesh Nebulization

Beike, H. et al. (2025).

Drug Delivery to the Lungs conference proceedings, Volume 36, 2025
 

To Publication

Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment

Neiens, V., Hansbauer, EM., Jaquin, T.J. et al. (2025).

Nat Commun 16, 3251 (2025).
                                          

To Publication

Long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution

Montaño, C., Bendstrup, E., Rønnov-Jessen, I. et al.

ERJ Open Res 2025; 11: 00567-2024
 

To Publication

eFlow Integrated – Aerosol Performance of a Novel Breath-Triggered Nebulizer

Heine, B., Oelhaf, S., Braeunlich, G., Steinfuehrer, K. (2024).

Drug Delivery to the Lungs (DDL), Edinburgh, UK, Dec 2024.
 

To Publication

Optimising inhalation adherence and technique: The power of digital technology

Fuchs, C., Ram, R. (2024).

ONdrugDelivery, Issue 162 (June 2024), pp 16–20.
 

To Publication

Deep breaths, deep dives: The new eFlow Integrated nebuliser

Bräunlich, G., Hahn, M. (2024).

ONdrugDelivery, Issue 158 (April 2024), pp 16–19.
 

To Publication

Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial.

Ringshausen, F.C., Shapiro, A.J., Nielsen, K.G., Mazurek, H., Pifferi, M., Donn, K.H. et al. (2023).

The Lancet Respiratory Medicine, Volume 12, Issue 1, P21-33, JANUARY 2024
 

To Publication

Large-eddy simulation, convective instability, and modal causality of coaxial supersonic air–water jets considering a swirl effect.

Yanchao, L., Xu, C., Wenkang, W., Weigand, B. (2023).

Physics of Fluids 35, 063316 (2023)
 

To Publication

Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates.

Seder, R.A., Gagne, M., Flynn, B.J., Andrew, S.F. et al. (2023).

bioRxiv preprint, November 8, 2023
 

To Publication

Aerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology.

Streblow, D.N., Hirsch, A.J., Stanton, J.J. et al. (2023).

Nat Commun 14, 7062 (2023).

To Publication

Transient Aerosol Measurements: Assessing the eFlow Nebulizer Aerosol Bolus.

Heine, B., Hein, C., Njoya, A. & Seemann, S. (2023).

ISAM 2023, International Society for Aerosols in Medicine, Saarbrücken, Germany, August 26-30, 2023.
 

To Publication

Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.

Mahri, S., Wilms, T., Hagedorm, P. et al. (2023).

European Journal of Pharmaceutical Sciences, Volume 189, 1 October 2023, 106522.
 

To Publication

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial.

West, A., Chaudhuri, N., Barczyk, A. et al. (2023).

Thorax, Published Online First: 22 March 2023
 

To Publication

Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis.

Schwarz, C., Procaccianti, C., Costa, L., Brini, R., Friend, R., Caivano, G., Sadafi, H., Mussche, C., Schwenck, N., Hahn, M., Murgia, X. & Bianci, F. (2022).

International Journal of Molecular Sciences 2022, 23(17), 9597
 

To Publication

A randomized controlled trial of liposomal cyclosporine A for inhalation in the prevention of bronchiolitis obliterans syndrome following lung transplantation.

Neurohr, C., Kneidinger, N., Ghiani, A., Monforte, V., Knoop, C., Jaksch, P., Parmar, J., Ussetti, P., Sole, A., Müller-Quernheim, J., Kessler, R., Wirtz, H., Boerner, G., Denk, O., Prante Fernandes, S. & Behr, J. (2022).

American Journal of Transplantation 2022;22:222–229.
 

To Publication

Inhaled Medicines: Past, Present, and Future.

Anderson, S., Atkins, P., Bäckman, P., Cipolla, D., Clark, A., Daviskas, E., Disse, B., Entcheva-Dimitrov, P., Fuller, R., Gonda, I., Lundbäck, H., Olsson, B. & Weers, J. (2022).

Pharmacological Reviews January 2022, 74 (1) 48-118.
 

To Publication

Unsteady Aerosol Output Rate Measurements: Assessing the eFlow Nebulizer Aerosol Bolus.

Heine, B., Keller, J., Dietsche, J., Winzen, A., Schuschnig, U. & Seemann, S. (2022).

Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation
 

To Publication

Towards More Realistic In Vitro Nebulizer Testing.

Schuschnig, U., Winzen, A., Heine, B., Schwenck, N. & Seemann, S. (2022).

Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation.
 

To Publication

Development of a Novel Test Stand for the Measurement of Valved Holding Chambers with Facemasks.

Winzen, A., Steinfuehrer, K., Schuschnig, U. & Seemann, S. (2022).

Respiratory Drug Delivery (RDD) 2022, Orlando, Florida, May 1-5, 2022 (in person), April 25-June 30, 2022 (virtual), Poster presentation.
 

To Publication

eFlow Technology Nebulisers with Digital Therapy Management: The PARI Connect Eco-System.

Fuchs, C., Buchner, S. (2021).

ONdrugDelivery, Issue 128 (Dec 2021), pp 10–14.
 

To Publication

Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.

Schwarz, C., Procaccianti, C., Mignot, B., Sadafi, H., Schwenck, N., Murgia, X. & Bianco, F. (2021).

Pharmaceutics 2021, 13(12).
 

To Publication

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.

Tashkin, D. P., Niu, X., Sharma, S. & Sanjar, S. (2021).

npj Primary Care Respiratory Medicine, volume 31, Article number: 43 (2021).
 

To Publication

Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.

Wildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., Mandefield, L., Sutton, L., Tappenden, P., Elliott, R. A., Hoo, Z., H., Drabble, S. J., Beever, D. & CFHealthHub Study Team (2021).

Thorax Published Online First: 23 September 2021.
 

To Publication

The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in Pseudomonas aeruginosa Isolates in Cystic Fibrosis.

Moore, J. E., Millar, B. C., Ollman-Selinger, M. & Cambridge, L. (2021).

Respiratory Care September 2021, 66 (9) 1446-1457.
 

To Publication

Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow^® Technology.

Li, Z., Perkins, W. & Cipolla, D. (2021).

European Journal of Pharmaceutics and Biopharmaceutics Volume 166, September 2021, Pages 10-18.
 

To Publication
 

To synopsis of the publication

Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub.

Arden, M. A., Hutchings, M., Whelan, P., Drabble, S. J., Beever, D., Bradley, J. M., Hind, D., Ainsworth, J., Maguire, C., Cantrill, H., O´Cathain, A. & Wildman, M. (2021).

Pilot and Feasibility Studies volume 7, Article number: 1 (2021).
 

To Publication

How Cold Is Cold Enough? Refrigeration of the Next-Generation Impactor to Prevent Aerosol Undersizing.

Schuschnig, U., Heine, B. & Knoch, M. (2021)

Journal of Aerosol Medicine and Pulmonary Drug Delivery, Published Online: June 7, 2021.
 

To Publication

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.

Hanania, N. A., Yohannes, A. M., Ozol-Godfrey, A., Tocco, M., Goodin, Th., Sharma, S. & Sanjar, S. (2021).

International Journal of Chronic Obstructive Pulmonary Disease 2021:16 865–875.
 

To Publication

Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.

Trapnell, B. C., Inoue, Y., Bonella, F., Morgan, C., Jouneau, S., Bendstrup, E., Campo, I., Papiris, S.A., Yamaguchi, E., Cetinkaya, E., Ilkovich, M. M., Kramer, M. R., Veltkamp, M., Kreuter, M., Baba, T., Ganslandt, C., Tarnow, I., Waterer, G. & Jouhikainen, T. (2020).

New England Journal of Medicine 2020; 383:1635-1644.
 

To Publication

Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow^® nebulizer.

Abd-Elaziz, K., Elberink, H. O. & Diamant, Z. (2020).

European Clinical Respiratory Journal 2020, VOL. 7, 1809083.
 

To Publication  

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow^® CS.

Stephenson, J.J., Dembek, C., Caldwell-Tarr, A., Conto, R.M., Paullin, M., Kerwin, E.M. (2020).

Int J Chron Obstruct Pulmon Dis. 2020 Jul 14;15:1713-1727. eCollection 2020.
 

To Publication

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis.

Kaminskas, L. M., Landersdorfer, C. B., Bischof, R. J., Leong, N., Ibrahim, J., Davies, A. N., Pham, S., Beck, S., Montgomery, B., Surber, M. W. (2020).

Pharmaceutical Research, volume 37, Article number: 3 (2020).
 

To Publication

Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.

Beck-Broichsitter, M. (2019).

Journal of Pharmaceutical Sciences 108 (2019) 2588-2592.
 

To Publication

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Khoo, J. K., Montgomery, A. B., Otto, K. L., Surber, M., Faggian, J., Lickliter, J. D., Glaspole, I. (2019).

Journal of aerosol medicine and pulmonary drug delivery, 32(0), 1-6.
 

To Publication

A randomised single-centre trial of inhaled liposomal cyclosporine for bronchiolitis obliterans syndrome post-lung transplantation.

Iacono, A., Wijesinha, M., Rajagopal, K., Murdock, N., Timofte, I., Griffith, B., Terrin, M. (2019).

ERJ Open Research 2019 5: 00167-2019.
 

To Publication

Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.

Barth, P., Bruijnzeel, P., Wach, A., Sellier Kessler, O., Hooftman, L., Zimmermann, J., Naue, N., Huber, B., Heimbeck, I., Kappeler, D., Timmer, W., Chevalier, E. (2019).

Journal of Cystic Fibrosis.
 

To Publication

Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates.

Vonarburg, C., Loetscher, M., Spycher, M. O., Kropf, A., Illi, M., Salmon, S., Roberts, S., Steinfuehrer, K., Campbell, I., Koernig, S., Bain, J., Edler, M., Baumann, U., Miescher, S., Metzger, D. W., Schaub, A., Käsermann, F. & Zuercher, A. W. (2019).

Respiratory Research 2019.
 

To Publication

In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution.

Pham, S., Ferguson, G. T., Kerwin, E., Goodin, T., Wheeler, A., & Bauer, A. (2018).

Journal of aerosol medicine and pulmonary drug delivery, 31(3), 162-169.
 

To Publication

Monitoring nebuliser usage & lung function in clinical trials.

Fuchs, C., & Koehler, Y. (2018).

ONdrugDelivery Publishing 2018, June 6th, 87, 66-70.
 

To Publication

Monitoring adherence to treatment regimen of inhaled medication use in a clinical trial with an investigational eFlow nebulizer (eTrack).

Fuchs, C., Brosig, M., Finke, M., Fiebig, D., Soni, P., Tutuncu, A., Saponjic, R., & Knoch, M. (2017).

European Respiratory Journal 2017, 50.
 

To Publication

Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.

Sawicki, G. S., Chou, W., Raimundo, K., Trzaskoma, B., & Konstan, M. W. (2015).

Journal of Cystic Fibrosis, 14(6), 777-783.
 

To Publication

In-vitro Study of Aerosolised Colistin Delivered to the Nasal Tract via a Pulsating Aerosol Delivery Device (Vibrent^®).

Schuschnig, U., Seidler, A., Seemann, S., & Knoch, M. (2015).

20th International Congress of the International Society for Aerosols in Medicine (ISAM), Munich, Germany, May 30 to June 3, 2015.
 

To Publication

Drug delivery to paranasal sinuses using pulsating aerosols.

Moeller, W., Schuschnig, U., Bartenstein, P., Meyer, G., Haeussinger, K., Schmid, O., & Becker, S. (2014).

Journal of aerosol medicine and pulmonary drug delivery, 27(4), 255-263.
 

To Publication

The eFlow ‘‘closed system’’(CS) - a novel device platform for liquid aerosol drug-device combinations.

Gallem, T. (2014).

ONdrugDelivery Publishing 2014, June 19th, 50,13-16 (ondrugdelivery.com).
 

To Publication

A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.

Griese, M., Eismann, C., Börner, G., Denk, O., Schierholz, J. M., Keller, M., Mazurek, H., & Kappler, M. (2014).

Journal of aerosol medicine and pulmonary drug delivery, 27(3), 185-192.
 

To Publication

Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.

Boerner, G., Prante, S., & Borella, F. (2014).

Journal of Cystic Fibrosis, 13, S121.

To Publication

Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.

Möller, W., Schuschnig, U., Celik, G., Münzing, W., Bartenstein, P., Häussinger, K., Kreyling, W. G., Knoch, M., Canis, M., & Becker, S. (2013).

PloS one, 8(9), e74991.
 

To Publication

Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.

Möller, W., Schuschnig, U., Becker, S., Saba, G. K., Münzing, W., Bartenstein, P., & Knoch, M. (2013).

Journal of aerosol medicine and pulmonary drug delivery, 26(4), 257-258.

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Mundt, C., Sventitskiy, A., Cehelsky, J. E., Patters, A. B., Tservistas, M., Hahn, M. C., Juhl, G., DeVincenzo, J. P. (2012).

ISRN pediatrics, 2012.

A Comparison of Amount and Speed of Deposition Between the PARI LC STAR^® Jet Nebulizer and an Investigational eFlow^® Nebulizer.

Coates, A. L., Green, M., Leung, K., Chan, J., Ribeiro, N., Ratjen, F., & Charron, M. (2011).

Journal of aerosol medicine and pulmonary drug delivery, 24(3), 157-163.
 

To Publication

Nasally inhaled pulsating aerosols: lung, sinus and nose deposition.

Moller, W., Saba, G. K., Haussinger, K., Becker, S., Keller, M., & Schuschnig, U. (2011).

Rhinology, 2011.
 

To Publication

Objective Evaluation of Adherence to Inhaled Liposomal Cyclosporin Therapy for Lung Transplant Patients in a Clinical Trial.

Fuchs, C., Prante, S., Pokorski, R., Lim, H., Denk, O., Seemann, S., & Knoch, M. (2011).

Pediatric Pulmonology, 46(34), 418.

Pulsating aerosols for drug delivery to the sinuses in healthy volunteers.

Möller, W., Schuschnig, U., Khadem Saba, G., Meyer, G., Junge-Hülsing, B., Keller, M., & Häussinger, K. (2010).

Otolaryngology - Head and Neck Surgery, 142(3), 382-388.
 

To Publication

Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation.

Behr, J., Zimmermann, G., Baumgartner, R., Leuchte, H., Neurohr, C., Brand, P., Herpich, C., Sommerer, K., Seitz, K., Menges, G., Tillmanns, S., Keller, M., & the Munich Lung Transplant Group (2009).

Journal of aerosol medicine and pulmonary drug delivery, 22(2), 121-130.
 

To Publication

A Novel Nebuliser for the Simultaneous Administration of siRNA and Supplemental Oxygen for RSV in Infants.

Tservistas, M., Hahn, M., DeVincenzo, J., Hetzer, U., Uhlig, M., Cehelsky, J., Walsh, E., Kreutzer, T., O`Connor, S., Knoch, M. (2009).

Drug Delivery to the Lungs - DDL20, Edinburgh, United Kingdom, December 9-11, 2009. Proceedings: 53-56.
 

To Publication

New advances in aerosolised drug delivery: vibrating membrane nebuliser technology.

Lass, J. S., Sant, A., & Knoch M. (2006).

Expert opinion on drug delivery, 3(5), 693-702.
 

To Publication

The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems.

Knoch, M., & Keller M. (2005).

Expert opinion on drug delivery, 2(2), 377-390.
 

To Publication